View from the Thoraxcenter: AHA 23 Late-breaking Science Wrap Up

Published: 20 Nov 2023

  • Views:

    Views Icon 736
  • Likes:

    Heart Icon 1
Average (ratings)
No ratings
Your rating

What's hot at #AHA23?

Join Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) as they review the late-breaking science data from AHA Scientific Sessions 2023. 

They interpret the evidence from five key trials, providing context, asking thought-provoking questions to translate the data into key take-home messages for practice and research.

Trials Covered
00:20 - DAPA-MI: Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack

06:30 - ORBITA-2: Percutaneous Coronary Intervention for Stable Angina: A Randomised, Placebo-Controlled Trial

12:39 - A Sub-Analysis of the Prospective ECLS-Shock Trial

16:13 - ARTESiA: Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

10:02 - SELECT: Semaglutide and Cardiovascular Outcomes in Patients With Overweight or Obesity Who Do Not Have Diabetes

We value your opinion! Share your feedback by commenting on this page or sending us an email at


You must be to comment. If you are not registered, you can register here.